Subcutaneous Skyrizi beneficial in delayed, non-responders to IV induction therapy for CD

CHARLOTTE, N.C. — Subcutaneous risankizumab as maintenance therapy was efficacious and well-tolerated in patients with Crohn’s disease who had a delayed response to induction, according to research at the ACG Annual Scientific Meeting.Previous results from the ADVANCE and MOTIVATE phase 3 induction studies determined IV risankizumab (Skyrizi, AbbVie) bested placebo in achieving clinical and endoscopic improvement at week 12 among patients with moderate to severe CD, Marla Dubinsky, MD, professor of pediatrics and gastroenterology at the Icahn School of Medicine at Mount Sinai,Read More